

ROTARIX® PRODUCT INFORMATION

Rotavirus Vaccine, live attenuated

NAME OF THE MEDICINE

ROTARIX, powder and solvent for suspension for oral administration
Rotavirus vaccine

DESCRIPTION

ROTARIX is a lyophilised preparation of the live attenuated RIX4414 strain of human rotavirus of the G1P[8] type for use in the prevention of rotavirus gastro-enteritis. The virus strain derived from the 89-12 strain is obtained by propagation on a well-characterised Vero cell line.

ROTARIX is presented as a white powder for reconstitution with a separately supplied calcium carbonate buffer solvent. The solvent is presented as a turbid liquid with a slow settling white deposit and a colourless supernatant.

Each 1 mL dose of the reconstituted vaccine contains not less than $10^{6.0}$ CCID₅₀ (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus. The vaccine also contains sucrose, dextran 40, sorbitol, amino acids, Dulbecco's Modified Eagle Medium, calcium carbonate, xanthan gum and water for injections.

The manufacture of this product includes exposure to bovine derived materials at the very early steps of the production process. No bovine materials are used in routine production. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product.

CLINICAL PHARMACOLOGY

Rotavirus is likely to affect all children up to the age of five years of age. The peak incidence of rotavirus gastro-enteritis is between 6-24 months of age. Dehydration from rotavirus gastro-enteritis can lead to hospitalisation, which is most common in children under 2 years of age.

Mechanism of Action

The immunologic mechanism by which *ROTARIX* protects against rotavirus gastro-enteritis is not entirely understood. A relationship between antibody responses to rotavirus vaccination and

protection against rotavirus gastro-enteritis has not been established. *ROTARIX*, which is derived from the most common human rotavirus type G1P[8], has been demonstrated to induce protective immunity against the G1P[8] type, also eliciting cross protection against other prevalent strains (See Clinical Trials).

CLINICAL TRIALS

Protective efficacy

Clinical studies have been conducted in Europe and Latin America to evaluate the protective efficacy of *ROTARIX* against any and severe rotavirus gastro-enteritis. Protective efficacy has been shown to be higher against severe rotavirus gastroenteritis than rotavirus gastroenteritis of any severity. Protective efficacy has been demonstrated against rotavirus of types G1P[8], G3P[8], G4P[8] and G9P[8] . Pooled analysis of four efficacy studies for efficacy against severe gastro-enteritis (Vesikari score ≥ 11) caused by rotavirus G2P[4] suggests efficacy against this type. (See Table 2).

A clinical study performed in Europe evaluated *ROTARIX* given according to different European schedules (2, 3months; 2, 4 months; 3, 4 months; 3, 5 months) in 3,994 subjects (2646 subjects receiving *ROTARIX* and 1348 subjects receiving placebo). Severity of gastro-enteritis was defined according to the Vesikari 20-point scale which evaluates the full clinical picture of rotavirus gastro-enteritis by taking into account the severity and duration of diarrhoea and vomiting, the severity of fever and dehydration as well as the need for treatment. The first dose was given between 6 and 14 weeks of age and the second dose was administered 4 to 8 weeks later.

After two doses of *ROTARIX*, the protective vaccine efficacy during the first year of life was 95.8% (95% CI: 89.6; 98.7) against severe gastro-enteritis (Vesikari score ≥ 11) and 87.1% (95% CI: 79.6; 92.1) against any rotavirus gastro-enteritis, 91.8% (95% CI: 84; 96.3) against rotavirus gastroenteritis requiring medical attention and 100% (95% CI: 81.8; 100) against hospitalisation due to rotavirus gastro-enteritis.

The type specific vaccine efficacy is presented in Table 1 below:

Table 1: Efficacy of *ROTARIX* against any and severe rotavirus gastro-enteritis – European study

Type	All rotavirus gastro-enteritis		Severe rotavirus gastro-enteritis	
	Efficacy (%) ²	95% CI ³	Efficacy (%)	95% CI
G1P[8]	95.6	87.9; 98.8	96.4	85.7; 99.6
G2P[4]	62.0	-124.4; 94.4	74.7	-386.2; 99.6
G3P[8]	89.9	9.5; 99.8	100.0	44.8; 100.0
G4P[8]	88.3	57.5; 97.9	100.0	64.9; 100.0
G9P[8]	75.6	51.1; 88.5	94.7	77.9; 99.4
Strains with P[8] genotype	88.2	80.8; 93.0	96.5	90.6; 99.1

1. Severe gastro-enteritis defined as a score ≥ 11 on the Vesikari scale
 2. Efficacy defined as 1-stratified Poisson rate ratio was analysed from 2 weeks after dose 2 up until

the end of the first year follow-up.
 3. CI: Confidence Interval

Although *ROTARIX* is a 2-dose vaccine, efficacy has been observed as from the first dose. In Europe, vaccine efficacy against rotavirus gastro-enteritis of any severity from dose 1 to dose 2 was 89.8% (95% CI: 8.9; 99.8).

A clinical study performed in Latin America evaluated *ROTARIX* in more than 20,000 subjects. The first dose was given between 6 and 12 weeks of age and the second dose was administered 4 to 8 weeks later. After two doses of *ROTARIX*, the protective vaccine efficacy against severe rotavirus gastro-enteritis requiring hospitalisation and/or rehydration therapy in a medical facility was 84.7% (95% CI: 71.7; 92.4). Protective efficacy of *ROTARIX* was maintained during the second year of life with a vaccine efficacy against severe rotavirus gastro-enteritis of 79.0% (95% CI: 66.4; 87.4).

The following table presents a pooled analysis of four efficacy studies showing the type specific vaccine efficacy against severe rotavirus gastro-enteritis.

Table 2: Vaccine efficacy against severe gastro-enteritis by serotype – pooled analysis of four studies¹.

Type	ROTARIX		Placebo		Vaccine Efficacy ²	
	N ³	n (%) ⁴	N	n (%)	%	(LL; UL) ⁵
G1P[8]	13218	19 (0.14)	10737	80 (0.75)	87.43	78.89; 92.86
G2P[4] ⁶	13218	6 (0.05)	10737	15 (0.14)	71.42	20.12; 91.11
G3P[8]	12973	2 (0.02)	10614	13 (0.12)	90.19	55.51; 98.94
G4P[8]	11581	1 (0.01)	10160	9 (0.09)	93.37	51.50; 99.85
G9P[8]	12973	17 (0.13)	10614	53 (0.50)	83.76	71.18; 91.28

1. Severe gastro-enteritis defined as ≥ 11 on the Vesikari Scale. Analysis period from 2 weeks after the 2nd dose to the end of the first year follow-up of according to protocol populations
2. Vaccine efficacy defined as 1-stratified Poisson rate ratio
3. N: Number of subjects included in each group
4. n (%): number (percent) of subjects with at least one specified severe rotavirus gastro-enteritis episode reported in each group
5. LL, UL: lower limit and upper limit of the exact 95% confidence interval
6. Point estimates and confidence intervals for vaccine efficacy against type G2P[4] for the four studies were: 100% (95% CI: -1858.0; 100), 100% (21.1; 100), 45.4% (-81.5; 86.6), and 74.7% (-386.2; 99.6)

ROTARIX does not protect against non-rotaviral gastro-enteritis, or against diarrhoea due to other infectious and non-infectious causes.

INDICATIONS

ROTARIX is indicated for the prevention of rotavirus gastroenteritis (see Clinical Trials).

CONTRAINDICATIONS

ROTARIX should not be administered to subjects with known hypersensitivity to any components of the vaccine (see DESCRIPTION), or to subjects having shown signs of hypersensitivity after previous administration of rotavirus vaccines.

ROTARIX should not be administered to subjects with any history of chronic gastrointestinal disease including any uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract.

As with other vaccines, administration of *ROTARIX* should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection, such as a cold, is not a contraindication for immunisation.

PRECAUTIONS

***ROTARIX* should under no circumstances be injected.**

The administration of *ROTARIX* should be postponed in subjects suffering from diarrhoea or vomiting.

Administration of *ROTARIX* may be considered with caution in infants with gastrointestinal illnesses, when, in the opinion of the physician, the risk of rotavirus infection by withholding the vaccine entails a greater risk to the infant. No safety or efficacy data are available for the administration of *ROTARIX* to infants with gastrointestinal illnesses.

No safety data are available in subjects with primary and secondary immunodeficiency states including HIV positive infants.

Excretion of the vaccine virus in the stools occurs after vaccination with peak excretion around the 7th day. Viral antigen particles detected by ELISA were found in 50% of stools after the first dose and 4% of stools after the second dose. When these stools were tested for the presence of live vaccine strain, 17% were positive. There is a theoretical risk for transmission to non-vaccinated contacts. Therefore *ROTARIX* should be administered with caution to infants with close contacts who are immunodeficient, such as household members who are immunocompromised or receiving immunosuppressive therapy. Contacts of recent vaccinees should be advised to observe personal hygiene (e.g. wash their hands after changing child's nappies).

In data gathered from 140 premature infants between 29 and 36 weeks gestation, the vaccine was well tolerated. The level of clinical protection remains unknown.

As with any vaccine, a protective immune response may not be elicited in all vaccinees (see CLINICAL TRIALS).

ROTARIX does not protect against gastro-enteritis due to pathogens other than rotavirus.

Carcinogenicity and Mutagenicity

ROTARIX has not been evaluated for carcinogenicity or mutagenicity.

Impairment of Fertility

ROTARIX has not been evaluated for its potential to impair fertility.

Genotoxicity

ROTARIX has not been evaluated for genotoxicity.

Use in Pregnancy (Category B2):

ROTARIX is not intended for use in adolescents or adults. Thus human data on use during pregnancy are not available and animal reproduction studies have not been performed.

Use in Lactation:

ROTARIX is not intended for use in adolescents or adults. Thus human data on use during lactation are not available.

Based on evidence generated in clinical trials, breast-feeding does not reduce the protection against rotavirus gastro-enteritis afforded by *ROTARIX*. Therefore, breast-feeding may be continued during the vaccination schedule.

Paediatric Use

ROTARIX is intended for use in infants in the first six months of life. *ROTARIX* should not be administered to children older than 24 weeks of age as safety has not been demonstrated, particularly in relation to risk of intussusception.

Use in the Elderly

ROTARIX is not intended for use in the elderly. Thus human data on use in the elderly are not available.

Interactions

Co-administration studies have demonstrated that *ROTARIX* can be given concomitantly with any of the following administered either as monovalent or as combination vaccines: diphtheria-tetanus-acellular pertussis vaccine (DTPa), *Haemophilus influenzae* type b vaccine (Hib), inactivated polio vaccine (IPV), hepatitis B vaccine, pneumococcal vaccine and meningococcal serogroup C vaccine. The studies demonstrated that the immune responses and the safety profiles of the administered vaccines were unaffected.

Clinical studies, involving more than 2,000 subjects, were performed where *ROTARIX* and oral polio vaccine (OPV) were administered two weeks apart. The immune response to *ROTARIX* and OPV was unaffected. In three immunogenicity studies, involving approximately 1,200 subjects, *ROTARIX* was concomitantly administered with OPV. The immune response to OPV, as well as the response to *ROTARIX* after the second dose, were unaffected. *ROTARIX* can be concomitantly administered with OPV if this is in accordance with local recommendations. In the absence of local recommendations, an interval of two weeks between the administration of OPV and *ROTARIX* should be respected.

Although antibodies to rotavirus may be detected in breast milk, the available data show no reduction in efficacy when *ROTARIX* is administered to breast-fed infants.

Effects on laboratory tests

ROTARIX has not been evaluated for effects on laboratory tests.

ADVERSE REACTIONS**Clinical Trial Experience**

A total of eleven placebo-controlled clinical trials involved the administration of more than 77,800 doses of *ROTARIX* to approximately 40,200 infants in the first six months of life. In two clinical trials, *ROTARIX* was administered alone. In other clinical trials, *ROTARIX* was co-administered with other paediatric vaccines (see Interactions).

ROTARIX is generally well tolerated.

In two clinical trials (Finland), *ROTARIX* was administered alone (administration of routine paediatric vaccines was staggered). The incidence of diarrhoea, fever and irritability was comparable to the control group receiving placebo. No increase in the incidence or severity of these events was seen with the second dose.

In the other nine clinical trials, (Europe, Canada, USA, Latin America, Singapore, South-Africa), *ROTARIX* was co-administered with other paediatric vaccines (see Interactions). The adverse reaction profile observed in these subjects was comparable to the subjects receiving the same paediatric vaccines and placebo.

Table 3: Adverse reactions per system organ class and frequency within a maximum of 43 days after vaccination

System Organ Class	Preferred term	Incidence in the Rotarix group (%)	Incidence in the placebo group (%)
Infections and infestations	upper respiratory tract infection	0.10	0.07
Psychiatric disorders	irritability	45.8	41.8
	crying	0.39	0.52
	sleep disorder	0.39	0.52
Nervous system disorders	somnolence	0.39	0.00
Respiratory, thoracic and mediastinal disorders	hoarseness	0.02	0.00
	rhinorrhoea	0.02	0.00
Gastrointestinal disorders	loss of appetite	15.9	11.5
	diarrhoea	5.1	3.4
	vomiting	8.5	9.7
	flatulence	2.07	0.78
	abdominal pain	1.3	0.52
	regurgitation of food	2.20	1.55
	constipation	0.52	0.00
Skin and subcutaneous tissue disorders	dermatitis	0.04	0.03
	rash	0.03	0.03
Musculoskeletal and connective tissue disorders	muscle cramp	0.02	0.00
General disorders and administration site conditions	fever*	9.2	6.8
	fatigue	1.30	2.58

*rectal temperature >38°C

The risk of intussusception has been evaluated in a large safety trial conducted in Latin America and Finland where 63,225 subjects were enrolled. This trial gave evidence of no increased risk of intussusception in the *ROTARIX* group when compared with the placebo group as shown in the table below.

Table 4: Confirmed cases of intussusception in recipients of *ROTARIX* as compared with placebo recipients (Rota-023)

Intussusception within 31 days after administration of:	ROTARIX N = 31,673	Placebo N = 31,552	Relative risk (95% CI)
First dose	1	2	0.50 (0.07; 3.80)

Second dose	5	5	0.99 (0.31; 3.21)
Intussusception up to one year of age	N=10,159	N=10,010	
First dose up to one year of age	4	14	0.28 (0.10; 0.81)
CI: confidence interval			

Post-marketing data

There are currently no post-marketing surveillance data available for *ROTARIX*.

DOSAGE AND ADMINISTRATION

Dosage

The vaccination course consists of two doses. The first dose should be given between 6 and 14 weeks of age. The interval between the two doses should not be less than 4 weeks. The vaccine course should be completed by the age of 24 weeks as safety has not been assessed in older children.

In clinical trials, spitting or regurgitation of the vaccine has rarely been observed and, under such circumstances, a replacement dose was not given. However, in the unlikely event that an infant spits out or regurgitates most of the vaccine dose, a single replacement dose may be given at the same vaccination visit.

It is strongly recommended that infants who receive a first dose of *ROTARIX* complete the 2-dose regimen with *ROTARIX*.

Administration

ROTARIX is for oral use only.

ROTARIX SHOULD UNDER NO CIRCUMSTANCES BE INJECTED.

There are no restrictions on the infant’s consumption of food or liquid, including breast milk, either before or after vaccination.

Instructions for use and handling

A white deposit and clear supernatant is observed upon storage of the syringe containing the solvent. The content of the syringe should be inspected visually both before and after shaking for any foreign particulate matter and/or abnormal physical appearance prior to administration.

The vaccine is for single use only. Any unused vaccine or waste material should be disposed of in accordance with local requirements.

The reconstituted vaccine should also be inspected visually for any foreign particulate matter and/or abnormal physical appearance prior to administration. In the event of either being observed, discard the vaccine.

This vaccine must not be mixed with other medicinal products.

Reconstitution instructions:

1. Remove the plastic cover from the vial containing the powder. Connect the transfer adapter onto the vial by pushing it downwards until the transfer adapter is properly and solidly placed.
2. With the stopper still attached, shake the syringe containing the suspension vigorously. The shaken suspension will appear as a turbid liquid with a slow settling white deposit.
3. Remove the stopper from the syringe. Connect the syringe onto the transfer adapter by pushing it firmly on this device.
4. Inject the entire contents of the syringe into the vial containing the powder.
5. With the syringe still attached, shake the vial and examine for complete suspension of the powder. The reconstituted vaccine will appear more turbid than the diluent alone. This appearance is normal.
6. Withdraw the entire mixture back into the syringe. Remove the syringe from the transfer adapter.
7. This vaccine is for oral administration only. The child should be seated in a reclining position. Administer the entire content of the syringe **ORALLY** (on the inside of the cheek).



“FOR ORAL ADMINISTRATION ONLY”

If the reconstituted vaccine is to be stored temporarily before administration, replace the stopper on the tip of the syringe. The syringe containing the reconstituted vaccine should be shaken gently again before ORAL administration. Do not inject.



1. Remove the plastic cover from the vial containing the lyophilised powder. Connect the transfer adapter onto the vial by pushing it downwards until the transfer adapter is properly and solidly placed.

2. With the stopper still attached, shake the syringe containing the suspension vigorously. The shaken suspension will appear as a turbid liquid with a slow settling white deposit.



3. Remove the stopper from the syringe. Connect the syringe onto the transfer adapter by pushing it firmly on this device.

4. Inject the entire contents of the syringe into the vial containing the lyophilised powder.

5. With the syringe still attached, shake the vial and examine for complete suspension of the powder. The reconstituted vaccine will appear more turbid than the diluent alone. This appearance is normal.



6. Withdraw the entire mixture back into the syringe. Remove the syringe from the transfer adapter.

7. This vaccine is for oral administration only. The child should be seated in a reclining position. Administer the entire content of the syringe orally (on the inside of the cheek). **“FOR ORAL ADMINISTRATION ONLY”**

OVERDOSAGE

Insufficient data are available.

PRESENTATION AND STORAGE CONDITIONS

Powder in glass vial (Type I, Ph. Eur.) with stopper (butyl rubber).

Solvent (1 mL) in glass pre-filled syringe (Type I, Ph. Eur.) with a plunger stopper (butyl rubber).

Transfer adapter for reconstitution.

Pack size of 1.

Store at 2°C to 8°C (Refrigerate. Do not freeze). Store in the original package, in order to protect from light.

Before reconstitution:

The solvent may be stored at either 2°C to 8°C or at ambient temperature (the storage temperature must not exceed 37°C).

Experimental data show that the powder is stable when stored at 37°C for 1 week. However, these data are not recommendations for storage.

After reconstitution:

After reconstitution, the vaccine should be administered promptly or kept in the refrigerator (2°C to 8°C). If it is not used within 24 hours, it should be discarded.

Experimental data show that the reconstituted vaccine could also be kept to 24 hours at ambient temperature (18°C to 25°C). However, these data are not recommendations for storage.

NAME AND ADDRESS OF THE SPONSOR

GlaxoSmithKline Australia Pty Ltd,
1061 Mountain Hwy
Boronia VIC 3155

DISTRIBUTED IN NEW ZEALAND BY:

GlaxoSmithKline NZ Limited
Auckland NZ

POISON SCHEDULE OF THE DRUG

Schedule 4.

This document was approved by the Therapeutic Goods Administration on 22 February 2007

®*ROTARIX* is a registered trademark of the GlaxoSmithKline group of companies.